NVS vs. AZN, ABT, PFE, ABBV, SNY, VRTX, REGN, MRK, GSK, and BMY
Should you be buying Novartis stock or one of its competitors? The main competitors of Novartis include AstraZeneca (AZN), Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Sanofi (SNY), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Merck & Co., Inc. (MRK), GSK (GSK), and Bristol-Myers Squibb (BMY). These companies are all part of the "pharmaceutical preparations" industry.
AstraZeneca (NASDAQ:AZN) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, community ranking, valuation, earnings and profitability.
20.4% of AstraZeneca shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 0.0% of Novartis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
AstraZeneca has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.
Novartis has a net margin of 31.33% compared to Novartis' net margin of 13.30%. AstraZeneca's return on equity of 32.15% beat Novartis' return on equity.
Novartis received 473 more outperform votes than AstraZeneca when rated by MarketBeat users. Likewise, 61.42% of users gave Novartis an outperform vote while only 58.06% of users gave AstraZeneca an outperform vote.
Novartis has higher revenue and earnings than AstraZeneca. Novartis is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.
AstraZeneca currently has a consensus target price of $81.00, indicating a potential upside of 5.33%. Novartis has a consensus target price of $115.00, indicating a potential upside of 12.12%. Given AstraZeneca's higher probable upside, analysts plainly believe Novartis is more favorable than AstraZeneca.
In the previous week, AstraZeneca had 16 more articles in the media than Novartis. MarketBeat recorded 22 mentions for AstraZeneca and 6 mentions for Novartis. Novartis' average media sentiment score of 0.56 beat AstraZeneca's score of 0.39 indicating that AstraZeneca is being referred to more favorably in the media.
AstraZeneca pays an annual dividend of $1.93 per share and has a dividend yield of 2.5%. Novartis pays an annual dividend of $2.43 per share and has a dividend yield of 2.4%. AstraZeneca pays out 94.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novartis pays out 32.8% of its earnings in the form of a dividend. AstraZeneca has increased its dividend for 1 consecutive years and Novartis has increased its dividend for 4 consecutive years.
Summary
Novartis beats AstraZeneca on 13 of the 21 factors compared between the two stocks.
Get Novartis News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Novartis Competitors List
Related Companies and Tools
